Trial · NCT03408132
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of treatment-emergent adverse events | Day -28 to Day 26 plus 6 weeks | Adverse events as assessed by CTCAE v4.03 |
| Secondary | Assessment of intestinal insufficiency and gut absorption | Day -28 to day 26 | Changes in the wet weight (g) of faecal excretion |
| Secondary | Assessment of intestinal insufficiency and gut absorption | Day -28 and day 26 | Changes from baseline in lean body mass by DEXA scan. |
| Secondary | Assessment of intestinal insufficiency and gut absorption | Day -28 and day 26 | Changes from baseline in bone mineral content by DEXA scan. |
| Secondary | Assessment of intestinal insufficiency and gut absorption | Day -28 and day 26 | Changes from baseline in fat mass by DEXA scan. |
| Secondary | Assessment of intestinal insufficiency and gut absorption | Day -28 to day 26 plus 6 weeks | Measure of body weight (kg) |
| Secondary | Assessment of intestinal insufficiency and gut absorption | Baseline (Day -6) to end of treatment (Day 26) | Measurement of urinary output (ml) |
| Secondary | Assessment of intestinal insufficiency and gut absorption | Baseline (Day -6) to end of treatment (Day 26) | Measurement of urinary electrolytes (sodium, potassium, calcium, magnesium) (mmol/d) |
| Secondary | Assessment of gut regeneration | Baseline (Day -7) to end of treatment period (Day 26) plus 6 weeks | Measurements of the plasma Citrulline (ng/ml) |
| Secondary | Maximum observed plasma concentration (Cmax) | Day 1 to end of treatment period (Day 26) | Cmax (ng/ml) |
| Secondary | Cumulative area under the plasma concentration (AUC) of FE 203799 from time 0 to 168 | Day 1 to end of treatment period (Day 26) | AUC0-168 (ng\*hr/ml) |
| Secondary | Terminal elimination half-life (T1/2) of FE 203799 | Day 1 to end of treatment period (Day 26) | T1/2 (h) |
| Secondary | Apparent total body clearance (CL) of FE 203799 from plasma | Day 1 to end of treatment period (Day 26) | CL (ml/hr) |
| Secondary | Apparent volume of distribution (Vd) of FE 203799 during terminal phase | Day 1 to end of treatment period (Day 26) | Vd (ml) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03408132/registered